Bifogade filer
Invitation to SynAct's interim report Q3 2023 presentation
Kurs
+1,88%
Likviditet
2,04 MSEK
Prenumeration
Kalender
| Est. tid* | ||
| 2026-02-18 | 07:30 | Bokslutskommuniké 2025 |
| 2025-10-30 | 07:30 | Kvartalsrapport 2025-Q3 |
| 2025-08-20 | 07:30 | Kvartalsrapport 2025-Q2 |
| 2025-05-28 | N/A | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2025-05-27 | N/A | Årsstämma |
| 2025-05-27 | 07:30 | Kvartalsrapport 2025-Q1 |
| 2025-02-18 | - | Bokslutskommuniké 2024 |
| 2024-12-13 | - | Extra Bolagsstämma 2024 |
| 2024-10-30 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-20 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-31 | - | Kvartalsrapport 2024-Q1 |
| 2024-05-24 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2024-05-23 | - | Årsstämma |
| 2024-02-23 | - | Bokslutskommuniké 2023 |
| 2023-10-24 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-04 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-26 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2023-05-25 | - | Årsstämma |
| 2023-05-05 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-17 | - | Bokslutskommuniké 2022 |
| 2023-01-12 | - | Extra Bolagsstämma 2022 |
| 2022-11-04 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-05 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-30 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-23 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2022-05-20 | - | Årsstämma |
| 2022-02-11 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-27 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-24 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2021-05-21 | - | Årsstämma |
| 2021-05-05 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-12 | - | Bokslutskommuniké 2020 |
| 2020-11-13 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-28 | - | Kvartalsrapport 2020-Q2 |
| 2020-05-14 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2020-05-13 | - | Årsstämma |
| 2020-05-05 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-11 | - | Bokslutskommuniké 2019 |
| 2019-11-15 | - | Kvartalsrapport 2019-Q3 |
| 2019-11-08 | - | Extra Bolagsstämma 2019 |
| 2019-08-30 | - | Kvartalsrapport 2019-Q2 |
| 2019-05-13 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2019-05-10 | - | Årsstämma |
| 2019-04-24 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-12 | - | Bokslutskommuniké 2018 |
| 2018-11-16 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-31 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-16 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2018-05-15 | - | Årsstämma |
| 2018-05-09 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-13 | - | Bokslutskommuniké 2017 |
| 2017-11-03 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-31 | - | Kvartalsrapport 2017-Q2 |
| 2017-05-12 | - | X-dag ordinarie utdelning SYNACT 0.00 SEK |
| 2017-05-11 | - | Årsstämma |
| 2017-05-11 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-09 | - | Bokslutskommuniké 2016 |
| 2016-11-04 | - | Kvartalsrapport 2016-Q3 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
SynAct Pharma AB (publ) ("SynAct") will publish its Q3 report for 2023 on October 24 at 07.30 CET.
The company will host a conference call and online presentation on the same day at 15.00 CET. Torbjørn Bjerke, CEO, CFO Björn Westberg and CSO Thomas Jonassen will give an update on the development progress and financial results and will include a Q&A. The presentation will be made available on the website following the event.
The webcast will be live via the link:
https://ir.financialhearings.com/synact-pharma-q3-2023
If you wish to participate via teleconference, please register on the link below. After registration you will be provided phone numbers and a conference ID to access the conference. You can ask questions verbally via the teleconference.
https://conference.financialhearings.com/teleconference/?id=5008604
For further information, please contact:
Torbjørn Bjerke
CEO, SynAct Pharma AB
Phone: +46 727 44 41 58
Email: TBJE@synactpharma.com
Email: investor.relations@synactpharma.com
About SynAct Pharma
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.